Drug intelligence / Profile preview

AFC-2

Development stage: Preclinical
Administration: Oral

Overview

AFC-2 is a specific fucoidan fraction isolated from the brown algae *Ascophyllum nodosum*, which is found along the North Atlantic coast. It is a sulfated polysaccharide primarily composed of fucose and xylose, with a sulfate content of approximately 17.0% and sulfation occurring predominantly at the C2 hydroxy group. In preclinical studies using hyperlipidemic mouse models, AFC-2 demonstrated significant anti-hyperlipidemic effects comparable to atorvastatin. Its mechanism of action involves the modulation of lipoprotein-metabolism-related enzymes and oxidative stress-related enzymes, as well as the preservation of gut flora diversity. It is being investigated for its potential therapeutic application in treating hyperlipidemia and associated metabolic disorders.

Other names: Ascophyllum nodosum fucoidan fraction 2

Beyond the preview

Go deeper on AFC-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFC-2.

Explore the full profile